VectorBuilder, a provider of gene delivery technologies, has opened a new office in Edinburgh. The expansion aims to bolster its presence in the UK and enhance the organization’s ability to serve a region that represents one of its strongest customer bases.

VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. The company has branches in North America, Europe, China, Japan, South Korea, Australia, and Israel. To date, it has served more than 50,000 customers, which include universities, research institutions, biotech and pharma companies, and governmental agencies.

“When scientists partner with VectorBuilder, they eliminate the pain points in vector cloning and gene delivery,” said Kristofer Mussar, COO of VectorBuilder. “Our research overcomes the bottlenecks in gene delivery so the scientific community can rely on us to benefit their research and drug development. We proudly participated in the first human trial of an innovative gene therapy drug candidate for Menkes disease, a devastating congenital disorder, as well as recently partnered with Stand Up Therapeutics to produce and supply gene therapy products for the treatment of paralysis on a global level.”

Having a presence in the UK will enable VectorBuilder to assist the scientific community in focusing on its core research activities while streamlining operational processes through its innovative gene delivery technologies. Additionally, being part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone, further enhances VectorBuilder’s commitment to supporting researchers by providing access to a dynamic ecosystem of scientific innovation and collaboration.

According to the company, this strategic move positions VectorBuilder to leverage the state-of-the-art facilities and world-class expertise available within the Technopole, fostering strong partnerships with leading academic institutions and biotech companies in the region.

“As a provider of AAV viral vectors, VectorBuilder has played a crucial role in freeing up our time to focus more on research by providing large quantities of high-quality viral vector for in vivo applications,” said Martin Madill, senior scientist at Purespring Therapeutics. “Having access to VectorBuilder solutions will enable researchers across the UK to spend more time on hypothesis-driven investigations and data analysis, rather than labor-intensive AAV production.”